Clinical Trial Update: Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

A Phase 2 dose/schedule finding study evaluating romiplostim for chemotherapy-induced thrombocytopenia in non-small cell lung cancer; results were posted in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Thrombocytopenia
• Non-small Cell Lung Cancer

Drugs mentioned

• Romiplostim (romiplostim)

Snippet

Sponsor: Amgen | Conditions: Lung Cancer, Chemotherapy-Induced Thrombocytopenia | Phase 2 | Status: COMPLETED | Results posted: 2010-10-21